

### Editor's key points

- ▶ Serotonin syndrome, more aptly named *serotonin toxicity*, is a potentially fatal drug-induced condition caused by too much serotonin in synapses in the brain. Patients present with a combination of neuromuscular, autonomic, and mental status symptoms.
- ▶ Most cases involve 2 drugs that increase serotonin in different ways or an overdose of 1 serotonin drug. Monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, and selective serotonin reuptake inhibitors are the most common culprits. The use of 2 high-dose serotonin drugs at the same time should be avoided.
- ▶ Prevention of serotonin toxicity is key. Education of prescribers and patients is important to avoid and detect serotonin toxicity.

# Demystifying serotonin syndrome (or serotonin toxicity)

Ai-Leng Foong PharmD Kelly A. Grindrod PharmD MSc  
Tejal Patel PharmD Jamie Kellar PharmD

## Abstract

**Objective** To review the symptoms of serotonin toxicity (commonly referred to as *serotonin syndrome*) and the causative drugs and their mechanisms of action, and to equip primary care providers with practical strategies to prevent and identify serotonin toxicity.

**Quality of evidence** PubMed and Google Scholar were searched for relevant articles on serotonin toxicity, the causes, and the differential diagnosis using search terms related to serotonin toxicity (*serotonin syndrome*, *serotonin toxicity*, *serotonin overdose*), causes (individual names of drug classes, individual drug names), and diagnosis (*differential diagnosis*, *neuroleptic malignant syndrome*, *anticholinergic toxicity*, *discontinuation syndrome*, *malignant hyperthermia*, *serotonin symptoms*). Experts in psychiatric medicine, psychiatric pharmacy, clinical pharmacology, and medical toxicology were consulted. Evidence is level II and III.

**Main message** Serotonin toxicity is a drug-induced condition caused by too much serotonin in synapses in the brain. Cases requiring hospitalization are rare, and mild cases caused by serotonin-mediated side effects are unlikely to be fatal. Patients present with a combination of neuromuscular, autonomic, and mental status symptoms. Serotonin-elevating drugs include monoamine oxidase inhibitors, serotonin reuptake inhibitors, and serotonin releasers. Most cases involve 2 drugs that increase serotonin in different ways; the most concerning combination is a monoamine oxidase inhibitor with a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor.

**Conclusion** Family physicians play a key role in identifying and preventing serotonin syndrome by teaching patients to recognize symptoms and monitoring patients throughout therapy.

**S**erotonin toxicity (commonly referred to as *serotonin syndrome*) is a potentially life-threatening drug-induced condition caused by too much serotonin in the synapses of the brain.<sup>1-3</sup> Patients present with a combination of neuromuscular, autonomic, and mental status symptoms. Most cases involve 2 drugs that increase serotonin in different ways or an overdose of 1 serotonin-elevating drug.<sup>1-3</sup> While the most common culprits are monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and selective serotonin reuptake inhibitors (SSRIs), the list of potential contributors is long and includes often-overlooked substances such as herbals and illicit drugs.<sup>1-3</sup>

Cases of serotonin syndrome resulting in hospitalization or death are rare. Most cases do not require medication intervention, but can be managed by stopping the drug or decreasing the dose. Mild toxicity appears to be rare but is likely under-reported, unrecognized, or confused with other syndromes.<sup>2</sup> The lack of agreed-upon diagnostic criteria, inconsistencies in clinical symptoms, and clinicians who are not trained to identify it mean that case reports are published even when patients do not experience serotonin toxicity, which complicates the literature.<sup>1,2,4</sup> With the ever increasing use of antidepressants

for mood and other conditions such as anxiety, pain, sleep, and menopausal hot flashes, clarity is needed to help health care professionals prevent, identify, and manage serotonin toxicity.<sup>5,6</sup>

The objective of this update is to review the symptoms of serotonin toxicity and the causative drugs and their mechanisms of action, and to equip primary care providers with practical strategies to prevent and identify serotonin toxicity.

### Quality of evidence

We searched PubMed and Google Scholar for relevant articles on serotonin toxicity, the causes, and the differential diagnoses. A selection of search terms related to serotonin toxicity (*serotonin syndrome, serotonin toxicity, serotonin overdose*), causes (individual names of drug classes, individual drug names), and diagnosis (*differential diagnosis, neuroleptic malignant syndrome, anticholinergic toxicity, discontinuation syndrome, malignant hyperthermia, serotonin symptoms*) was used. We consulted with experts in psychiatric medicine, psychiatric pharmacy, clinical pharmacology, and medical toxicology. Recommendations were based on the criteria outlined by *Canadian Family Physician*, where level I evidence includes at least 1 properly conducted randomized controlled trial, systematic review, or meta-analysis; level II includes other comparison trials and non-randomized, cohort, case-control, or epidemiologic studies, and preferably more than 1 study; and level III includes expert opinion or consensus statements. Recommendations are based on level II and III evidence.

### Main message

We developed the infographic in **Figure 1** based on the best available evidence (**Table 1**).<sup>1-4,7-12</sup> The infographic and an English-only patient handout are available at **CFPlus**.\*

**Assess the patient.** The best available information on the symptoms of serotonin toxicity is from a retrospective analysis of prospective data collected by the Hunter Area Toxicology Service in Australia (level II evidence).<sup>1</sup> Patients present with a triad of neuromuscular, autonomic, and mental status changes that start within hours to 1 day of increasing a dose or adding a serotonergic drug (**Table 2**).<sup>1,2,12,13</sup> If untreated, serotonin toxicity escalates quickly and can be fatal.<sup>2</sup> Because toxicity presents on a spectrum rather than as a defined set of signs and symptoms (ie, a syndrome), *serotonin toxicity* is more accurate than *serotonin syndrome*.<sup>1</sup>

Mild symptoms, which include nervousness, insomnia, nausea, diarrhea, tremor, and dilated pupils, can

progress to moderate symptoms such as hyperreflexia (increased reflexes), sweating, agitation, restlessness, clonus (rhythmic muscle spasms), and ocular clonus (side-to-side eye movements). Patients with severe symptoms should be referred to the hospital immediately; severe symptoms include temperature greater than 38.5°C (101.3°F), confusion, delirium, sustained clonus or rigidity, and rhabdomyolysis.

Cases of serotonin toxicity that require hospitalization are straightforward to diagnose, as severe symptoms (such as bilateral, symmetric clonus in the legs more than in the arms) are not common in other conditions. The combination of nonspecific autonomic manifestations, a range of possible signs and symptoms, and a lack of definitive laboratory tests makes milder cases less straightforward to diagnose, although such cases are unlikely to be fatal.

**Assess the drug.** Because serotonin toxicity is a drug-induced condition, an accurate drug history is necessary for diagnosis, especially when a patient has recently used an MAOI or another serotonin-elevating drug. Serotonin toxicity most often happens when 2 or more serotonin-elevating drugs are used together, especially if they increase serotonin in different ways.<sup>1,2,12,13</sup> An MAOI with an SSRI, an SNRI, or another MAOI is the riskiest combination, but other combinations can also result in toxicity. Some experts report that therapeutic doses of a single drug can cause toxicity, but the risk is low, as it is a dose-related drug toxicity.<sup>1,2,14</sup>

Serotonin is formed from dietary tryptophan and stored in the presynaptic terminal.<sup>15</sup> It is released into the synapse where it acts on the presynaptic and postsynaptic terminals, and is taken back up into the presynaptic terminal to be degraded by monoamine oxidase (**Figure 2**).<sup>15</sup> Drugs that increase synaptic concentrations of serotonin include MAOIs, serotonin reuptake inhibitors, and serotonin releasers.<sup>4</sup>

**Monoamine oxidase inhibitors:** Monoamine oxidase inhibitors slow the breakdown of serotonin by blocking monoamine oxidase.<sup>15</sup> This class of drugs is most concerning, specifically MAOIs that bind irreversibly and non-selectively to both types of monoamine oxidase (MAO-A and MAO-B); MAO-A inhibitors are more likely to cause toxicity because MAO-A plays a larger role in the breakdown of serotonin.<sup>1,15</sup> Combination of 2 MAOIs or an MAOI and another serotonergic drug carries the greatest risk of serotonin toxicity. Although not common anymore, the most recognizable MAOIs are those used to treat depression, such as phenelzine, isocarboxazid, tranylcypromine, and moclobemide. Other agents less frequently recognized as MAOIs include the antibiotics isoniazid (irreversible, non-selective) and linezolid (reversible, non-selective).<sup>3,16</sup>

\*The infographic (**Figure 1**) and an English-only patient handout are available at [www.cfp.ca](http://www.cfp.ca). Go to the full text of the article online and click on the **CFPlus** tab.

Figure 1

# Target Serotonin Syndrome

def. Toxicity caused by excessive serotonin levels that results from a drug overdose or interaction

**Assess the patient** Symptoms start within hours to 1 day of increasing a dose or adding a drug

## Mild

Nervousness  
Insomnia  
Nausea/diarrhea  
Tremor  
Big pupils

## Moderate

Hyperreflexia  
Sweating  
Agitation/restlessness  
Inducible clonus  
Side-to-side eye movements

## Severe

Fever >38.5°C/101.3°F  
Confusion/delirium  
Sustained clonus/rigidity  
Rhabdomyolysis  
**Death**

**Assess all drugs** Most cases involve 2 drugs that increase serotonin in different ways – full list on back



Prescription drugs



OTC and natural drugs



Illicit drugs

**Rule out** Serotonin syndrome can look like other things; diagnosis requires an accurate drug history

Antidepressant Discontinuation  
Anticholinergic Toxicity  
Malignant Hyperthermia  
Neuroleptic Malignant Syndrome  
Meningitis/Encephalitis  
Drug Overdose  
Alcohol/Benzo Withdrawal

Similar-looking conditions

Remind all patients:

Non-toxic increases in serotonin can cause anxiety, restlessness and irritability for 1-2 weeks

**If you suspect serotonin syndrome** Don't wait, take action – it progresses rapidly



Stop the drug(s)



Refer patient to hospital



once symptoms are gone

Try other drugs or restart low doses slowly

**Prevent serotonin syndrome** Stay alert – most cases can be prevented

- ✓ Use lowest effective dose
- ✓ Check drug monographs for tapering and wash-out periods
- ✓ Reassess the need for a serotonin drug yearly
- ✓ Ask about illicit drug use
- ✓ Follow up 1-2 days after upping a dose or starting a new drug
- ✓ Teach patients to recognize serotonin syndrome

**AVOID:** **Group A** with **Group A** or **Group A** with **Group B**

**CAUTION:** TWO or more **Group B** drugs especially when ONE is used at a high dose

**MONITOR:** If a patient uses a **Group B** drug and a second **Group B** drug is added, start low, increase the dose cautiously, and watch for symptoms for 24-48h after every change

## Group A

Non-selective and irreversible

MAOI A and B

Isocarboxazid

Isoniazid

Phenelzine

Tranylcypromine

Non-selective and reversible

MAOI A and B

Linezolid

Selective and irreversible MAOI B


Selegiline (non-selective at higher doses)

Rasagiline

Selective and reversible MAOI A

Moclobemide

Methylene blue (non-selective at higher doses)



## Group B

Antidepressants

Selective Serotonin Reuptake Inhibitors (SSRI): Paroxetine, fluvoxamine, sertraline, citalopram, escitalopram, fluoxetine

Serotonin Norepinephrine Inhibitors (SNRI): Venlafaxine, desvenlafaxine, duloxetine

Tricyclic Antidepressants: Clomipramine, imipramine

Opioids and other pain medications

Tramadol, meperidine, methadone, fentanyl (unlikely with morphine, codeine, oxycodone, buprenorphine)

Cough, cold and allergy

Dextromethorphan ("DM"), chlorpheniramine

Natural health products

St. John's wort, L-tryptophan, diet pills

Illicit drugs

Ecstasy (MDMA), amphetamine, cocaine

Commonly listed but unlikely to cause serotonin syndrome

Triptans (e.g., sumatriptan)

Antidepressants: amitriptyline, mirtazapine, trazodone

Antiemetics: 5HT<sub>3</sub> receptor antagonists (e.g., ondansetron), metoclopramide

Buspirone, lithium

Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med* 2005; 352:1112-20.

Gardner DM. Serotonin Syndrome.

Gillman K. A systematic review of the serotonergic effects of Mirtazapine. *Hum Psychopharmacol Clin Exp* 2005; 21(2):117-25.

Gillman K. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. *Headache* 2010; 50(2):264-72.

Gillman K. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *Br J Anaesth* 2005 Oct;95(4):434-41.

Gillman K. CNS toxicity involving methylene blue. *J Psychopharmacol*. 2011 Mar;25(3):429-36.

Harada T et al. Incidence and predictors of activation syndrome induced by antidepressants. *Depress Anxiety* 2008; 25:1014-19.

Isbister GK et al. Serotonin toxicity: a practical approach to diagnosis and treatment. *Med J Aust* 2007;187(6):361-5.

Sinclair LI et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J Psychiatry* 2009; 194:483-90.

Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria. *QJM*. 2003;96(9):635-642.

Content by Kelly Grindrod, PharmD; Tejal Patel, PharmD; Jamie Kellar, PharmD; Ai-Leng Foong, BSc. Design by Adrian Poon, BA

**Table 1. Evidence supporting the key considerations for practice**

CLINICAL CONSIDERATIONS	EVIDENCE RATING	REFERENCES
The best available evidence for the clinical presentation of toxicity is from the Hunter Area Toxicology Service in Australia	Level II*	1
Serotonin toxicity most often happens when 2 serotonin-elevating drugs are used together. The use of an MAOI with an SSRI, an SNRI, or another MAOI is the most concerning drug combination	Level III†	1,3
Some drugs thought to cause serotonin toxicity do not (eg, triptans, ondansetron)	Level III†	1,4,7-11
Prevention of serotonin toxicity through good prescribing practices and monitoring is important	Level III†	2,12

MAOI—monoamine oxidase inhibitor, SNRI—serotonin-norepinephrine reuptake inhibitor, SSRI—selective serotonin reuptake inhibitor.

\*Level II: Comparison trials other than randomized controlled trials, systematic reviews, or meta-analyses; non-randomized, cohort, case-control, or epidemiologic studies; and preferably more than 1 study.

†Level III: Expert opinion or consensus statements.

**Table 2. Signs and symptoms of serotonin toxicity**

CATEGORY	SIGNS AND SYMPTOMS
Neuromuscular	<ul style="list-style-type: none"> <li>• Tremor</li> <li>• Hyperreflexia (increased reflexes)*</li> <li>• Clonus (rhythmic muscle spasms that can be spontaneous, inducible, or ocular)*</li> </ul>
Autonomic	<ul style="list-style-type: none"> <li>• Mydriasis (dilated pupils)</li> <li>• Diaphoresis (sweating)</li> <li>• Tachycardia (increased heart rate)</li> <li>• Tachypnea (increased breathing rate)</li> </ul>
Mental status	<ul style="list-style-type: none"> <li>• Agitation</li> <li>• Excitement</li> <li>• Restlessness</li> <li>• Confusion</li> <li>• Delirium</li> </ul>

Data from Dunkley et al,<sup>1</sup> Boyer and Shannon,<sup>2</sup> Ables and Nagubilli,<sup>12</sup> and Isbister et al.<sup>13</sup>

\*Hyperreflexia and clonus are often worse in the legs than in the arms.

**Serotonin reuptake inhibitors:** Serotonin reuptake inhibitors prevent the transport of serotonin from the synapse back into the presynaptic terminal to be degraded, keeping it at the site of action.<sup>15</sup> Drugs that prevent the reuptake of serotonin include SNRIs, SSRIs, tramadol, certain tricyclic antidepressants (TCAs), certain opioids, dextromethorphan, the antihistamines chlorpheniramine and brompheniramine, and herbals such as St John’s wort.<sup>7,13</sup>

After MAOIs, SNRIs and SSRIs are the most concerning serotonergic drugs, as their main mechanism is to increase serotonin.<sup>1,2</sup> The SNRI venlafaxine causes toxicity more often than SSRIs do, possibly because it has another serotonergic mechanism other than a reuptake inhibitor.<sup>3</sup>

Certain synthetic opioids such as tramadol, methadone, meperidine, fentanyl, and dextromethorphan are weak serotonin reuptake inhibitors and can cause toxicity, but opioids with a structure similar to morphine are not reuptake inhibitors, meaning that morphine, codeine, oxycodone, and buprenorphine do not cause toxicity.<sup>7</sup> Because of the risk of dextromethorphan and the antihistamines chlorpheniramine and brompheniramine, remind patients who take serotonin drugs to talk to

a physician or pharmacist before taking a cough and cold medication.

Tricyclic antidepressants are also serotonin reuptake inhibitors, with clomipramine and imipramine being the most potent and likely the only TCAs to be involved in serotonin toxicity; other TCAs such as amitriptyline are weaker inhibitors and are thus unlikely to cause toxicity.<sup>3,7</sup>


**Serotonin releasers:** Serotonin releasers cause more serotonin to be released from the presynaptic terminal into the synapse. Serotonin releasers include amphetamine, but not methylphenidate, and the illicit drug ecstasy (3,4-methylenedioxymethamphetamine).<sup>3,7,12</sup>

**L-Tryptophan:** A drug that does not fit into any of these 3 categories is L-tryptophan, which can be used for various mood disorders.<sup>3</sup> L-Tryptophan can increase serotonin levels because serotonin is made from tryptophan; however, the risk is low.

**Controversies.** Experts disagree on the list of implicated drugs. The lists of serotonin drugs published by the US Food and Drug Administration (FDA) and Health Canada include drugs that are unlikely to cause toxicity based on their mechanisms of action—either they work on different receptors than the ones involved in serotonin toxicity or they block rather than activate the receptors.<sup>8,9</sup> Examples include triptans (used for migraines), antiemetics such as ondansetron, olanzapine, mirtazapine, cyclobenzaprine, bupropion, trazodone, buspirone, lithium, and amitriptyline.<sup>1,4,7-11</sup> That these are unlikely to cause serotonin toxicity is supported by the lack of case reports implicating these drugs, through case series, by reviewing the evidence for case reports, and by understanding the pharmacology of these drugs.

In 2016, an FDA warning<sup>8</sup> stated that opioids interact with migraine medications (triptans), a warning partly based on poor-quality case reports that did not use validated criteria (eg, the Hunter Serotonin Toxicity Criteria) to diagnose serotonin toxicity.<sup>4</sup> Similarly, the FDA, Health Canada, and the World Health Organization issued warnings about 5-HT<sub>3</sub> antagonists (eg, antiemetics such as ondansetron and granisetron) despite a lack of high-quality evidence of this drug class causing toxicity.<sup>8-10,17,18</sup>

**Figure 2. Serotonin physiology:** Serotonin is formed in the presynaptic terminal from tryptophan. Once packaged into vesicles, it is released into the synaptic cleft where it can bind to serotonin receptors on the postsynaptic neuron to exert its action. Serotonin is transported through a transporter to the presynaptic terminal where it is broken down by monoamine oxidase.<sup>15</sup> The 3 classes of drugs that increase serotonin in synapses are highlighted in red.



5HT—5-hydroxytryptamine.

Based on these controversial data, there is a risk that inaccurate information has been incorporated into drug interaction-checking software used in pharmacies and physicians' offices. In Canada, RxVigilance and First Databank maintain updated databases that are used in electronic decision support tools for health care providers, such as the drug information needed for an interaction checker.<sup>19,20</sup> Although these companies recognize that the FDA and Health Canada have published information based on weak evidence, their interaction checkers still flag combinations of drugs that are unlikely to cause serotonin toxicity. As a result, prescribers might avoid prescribing a medication that might otherwise prove to be useful for a patient.

**What to rule out.** Other conditions look similar to serotonin toxicity.

**Antidepressant discontinuation:** Symptoms start within days of stopping or tapering a drug and are usually self-limited, lasting 1 week.<sup>21</sup> Symptoms include flu-like symptoms, nausea, imbalance, sensory disturbances, hyperarousal, and changes in mood, sleep, and appetite.<sup>21</sup>

**Anticholinergic toxicity:** Anticholinergic toxicity results from an overdose of anticholinergic medications. Symptoms include dry mouth, dry and flushed skin, urinary retention, decreased bowel sounds, dilated pupils, blurry vision, fever, agitation, delirium, and hallucinations.<sup>22</sup> A distinguishing feature is that muscle tone and reflexes are normal in anticholinergic toxicity.<sup>22</sup>

**Malignant hyperthermia:** Malignant hyperthermia is triggered by specific volatile anesthetics during or shortly after surgery. Telltale signs include hyperthermia (>39°C), tachycardia, tachypnea, acidosis, muscle rigidity, and rhabdomyolysis.<sup>23</sup> Family history is a factor.

**Neuroleptic malignant syndrome:** Unlike serotonin toxicity, neuroleptic malignant syndrome is not dose-related but is an idiosyncratic reaction to neuroleptic drugs. Onset is slower, taking place over days, and it is differentiated from serotonin toxicity by the presence of bradykinesia and lead-pipe or cogwheel rigidity.<sup>23</sup>

**Other conditions:** Other similar-looking conditions include meningitis or encephalitis, drug overdose, and alcohol or benzodiazepine withdrawal.<sup>12,13</sup> Notably, it is normal for nontoxic increases in serotonin to cause anxiety, restlessness, and irritability for 1 to 2 weeks after starting a drug or increasing a dose.<sup>24</sup>

**If you suspect serotonin toxicity.** If you suspect serotonin toxicity, stop the serotonin drugs. Refer patients with severe symptoms or patients who have ingested an MAOI and a serotonin reuptake inhibitor to the hospital, as their condition can worsen quickly.<sup>13</sup> Teach patients to recognize serotonin toxicity and tell them to call their primary practitioner if they suspect toxicity. Once signs and symptoms have resolved, try other drugs or restart low doses slowly, and rule out other contributing drugs

such as over-the-counter medications or illicit drugs. For most patients who experience serotonin-mediated side effects, these changes to their medications will manage symptoms and prevent toxicity, and a hospital referral will not be required.

**Preventing serotonin toxicity.** Serotonin toxicity remains a confusing area for practitioners and can be a scary, potentially fatal experience for patients. As most cases are avoidable, learning to identify and prevent it is key.


**Before prescribing a serotonin drug and at check-ups:** Ask patients about over-the-counter drug, herbal, and illicit drug use. Remind patients to check with their prescribers or pharmacists before starting a new drug.

**When prescribing:** Make sure you use the lowest effective dose and avoid the use of 2 high-dose serotonin drugs at the same time.

**If stopping or switching drugs:** Check drug monographs for tapering and wash-out periods, and stress careful adherence to the crossover schedule.

**After prescribing:** Follow up with patients a few days after increasing the dose or starting a new drug, and check yearly if the patient still needs to be taking the drug.

## Conclusion

Serotonin toxicity is an important topic for primary care providers. Education of both practitioners and patients is the only way to prevent serotonin toxicity. 

**Dr Foong** completed her Doctor of Pharmacy degree at the University of Waterloo School of Pharmacy in Ontario. **Dr Grindrod** is Assistant Professor in the University of Waterloo School of Pharmacy and a clinical pharmacist at the Kitchener Downtown Community Health Centre. **Dr Patel** is Assistant Clinical Professor in the University of Waterloo School of Pharmacy, part-time Assistant Clinical Professor in the Michael G. DeGroote School of Medicine at McMaster University, a clinical pharmacist with the Memory Clinic at the Centre for Family Medicine Family Health Team in Kitchener, a research scientist at the Schlegel-University of Waterloo Research Institute for Aging, and an affiliate researcher with the Waterloo Institute for Complexity and Innovation. **Dr Kellar** is Assistant Professor and Acting Director of the Doctor of Pharmacy program at the Leslie Dan Faculty of Pharmacy at the University of Toronto in Ontario, an advanced practice hospital pharmacist at the Centre for Addiction and Mental Health in Toronto, a doctoral candidate in the School of Health Professions Education at Maastricht University in the Netherlands, and a research fellow at the Wilson Centre in Toronto.

### Acknowledgment

We thank **Adrian Poon**, who designed the infographic and serotonin physiology figure; **Dr David Gardner**, who provided comments on our infographic; and **Dr Ken Gillman**, who provided comments on our manuscript. Dr Gardner's website, Medication InfoShare ([www.medicationsinfo.com](http://www.medicationsinfo.com)), provides resources and research about mental health and medications. Dr Gillman's extensive research on serotonin toxicity is compiled on his website, PsychoTropical Research ([www.psychotropic.info](http://www.psychotropic.info)).

### Contributors

**Dr Grindrod** conceived of the project. All authors were involved in drafting the infographic and the manuscript and approving the final draft.

### Competing interests

None declared

### Correspondence

**Dr Kelly A. Grindrod**; e-mail [kgrindrod@uwaterloo.ca](mailto:kgrindrod@uwaterloo.ca)

### References

- Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. *QJM* 2003;96(9):635-42.
- Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med* 2005;352(11):1112-20. Errata in: *N Engl J Med* 2007;356(23):2437, *N Engl J Med* 2009;361(17):1714.
- Gillman PK. A review of serotonin toxicity data: implication for the mechanisms of antidepressant drug action. *Biol Psychiatry* 2006;59(11):1046-51. Epub 2006 Feb 7.
- Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. *Headache* 2010;50(2):264-72. Epub 2009 Nov 17.

5. Morkem R, Barber D, Williamson T, Patten SB. A Canadian Primary Care Sentinel Surveillance Network study evaluating antidepressant prescribing in Canada from 2006 to 2012. *Can J Psychiatry* 2015;60(12):564-70.
6. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. *Arch Gen Psychiatry* 2010;67(1):26-36.
7. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *Br J Anaesth* 2005;95(4):434-41. Epub 2005 Jul 28.
8. U.S. Department of Health and Human Services. *FDA drug safety communication: FDA warns about several safety issues with opioid pain medicines; requires label changes*. Silver Spring, MD: U.S. Food and Drug Administration; 2016. Available from: [www.fda.gov/Drugs/DrugSafety/ucm489676.htm](http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm). Accessed 2017 Jul 27.
9. Health Canada. *Summary safety review—serotonin blocking drugs (serotonin antagonists) ALOXI (palonosetron), ANZEMET (dolasetron), KYTRIL (granisetron) and generics, and ZOFTRAN (ondansetron) and generics—serotonin syndrome*. Ottawa, ON: Health Canada; 2014.
10. Gillman PK. *Regulatory agencies (WHO, FDA) offer ill-conceived advice about serotonin toxicity (serotonin syndrome) with 5-HT3 antagonists: a worldwide problem*. PsychoTropical Research; 2015. Available from: <http://psychotropic.info/serotonin-toxicity-and-5-ht3-antagonists>. Accessed 2017 Jul 27.
11. Gillman PK. Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity? *Am J Emerg Med* 2009;27(4):509-10.
12. Ables AZ, Nagubilli R. Prevention, diagnosis and management of serotonin syndrome. *Am Fam Physician* 2010;81(9):1139-42.
13. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. *Med J Aust* 2007;187(6):361-5.
14. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. *J Toxicol Clin Toxicol* 2004;42(3):277-85.
15. Sanders-Bush E, Hazelwood L. 5-Hydroxytryptamine (serotonin) and dopamine. In: Brunton LL, Chabner BA, Knollmann BC, editors. *Goodman & Gilman's. The pharmacological basis of therapeutics*. 12th ed. New York, NY: McGraw-Hill; 2011. p. 335-62.
16. Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. *J Clin Psychopharmacol* 2011;31(1):66-74.
17. WHO Collaborating Centre for International Drug Monitoring. *WHO pharmaceuticals newsletter*. No. 3, 2012. Geneva, Switz: World Health Organization; 2012. Available from: [www.who.int/medicines/publications/Newsletter\\_3\\_2012.pdf](http://www.who.int/medicines/publications/Newsletter_3_2012.pdf). Accessed 2017 Jul 27.
18. WHO Collaborating Centre for International Drug Monitoring. *WHO pharmaceuticals newsletter*. No. 4, 2012. Geneva, Switz: World Health Organization; 2012. Available from: [www.who.int/medicines/publications/PharmNewsNo4\\_2014.pdf](http://www.who.int/medicines/publications/PharmNewsNo4_2014.pdf). Accessed 2017 Jul 27.
19. *Vigilance Santé* [database and software]. Repentigny, QC: Vigilance Santé; 2017. Available from: [www.vigilance.ca](http://www.vigilance.ca). Accessed 2017 Aug 14.
20. *First Databank* [database]. South San Francisco, CA: First Databank; 2018. Available from: [www.fdbhealth.com](http://www.fdbhealth.com). Accessed 2017 Aug 14.
21. Kok RM, Reynolds CF 3rd. Management of depression in older adults: a review. *JAMA* 2017;317(20):2114-22.
22. Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium—theory, evidence, and practice. *Br J Clin Pharmacol* 2015;81(3):516-24. Epub 2015 Dec 29.
23. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. *Mov Disord* 2010;25(12):1780-90.
24. Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J Psychiatry* 2009;194(6):483-90.

---

This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to [www.cfp.ca](http://www.cfp.ca) and click on the Mainpro+ link.

This article has been peer reviewed. *Can Fam Physician* 2018;64:720-7

La traduction en français de cet article se trouve à [www.cfp.ca](http://www.cfp.ca) dans la table des matières du numéro d'octobre 2018 à la page e422.